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Background: The quality of communication in medical care has been shown to influence health outcomes. Cancer
patients, a highly diverse population, communicate with their clinical care team in diverse ways over the course of
their care trajectory. Whether that communication happens and how effective it is may relate to a variety of factors
including the type of cancer and the patient’s position on the cancer care continuum. Yet, many of the routine
needs of cancer patients after initial cancer treatment are often not addressed adequately. Our goal is to identify
areas of strength and areas for improvement in cancer communication by investigating real-time cancer
consultations in a cross section of patient-clinician interactions at diverse study sites.
Methods/design: In this paper we describe the rationale and approach for an ongoing observational study involving
three institutions that will utilize quantitative and qualitative methods and employ a short-term longitudinal,
prospective follow-up component to investigate decision-making, key topics, and clinician-patient-companion
communication dynamics in clinical oncology.
Discussion: Through a comprehensive, real-time approach, we hope to provide the fundamental groundwork from
which to promote improved patient-centered communication in cancer care.
Keywords: Cancer, Oncology, Physician-patient communicationBackground
“You have cancer.” Approximately 1.6 million people in
the United States heard these frightening words in 2012
in the context of a new cancer diagnosis [1]. In delivering
a diagnosis, making decisions about life-altering treat-
ment, and ultimately helping patients navigate through
diagnosis, treatment, survivorship, and/or end-of-life care,
oncology clinicians carry a deep responsibility to offer in-
formation and support in a manner that will be most help-
ful to their patients – a task which must be individualized
for each interaction. Clinicians serve as technical experts,
while patients hold expert knowledge about their own* Correspondence: tilburt.jon@mayo.edu
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reproduction in any medium, provided the orfeelings, life circumstances and preferences; both play a
crucial role informing in treatment decisions. Family and
friends can also play an important contributing role in the
process of diagnostic and treatment decision-making and
in offering support in the midst of and after treatment.
Clinicians can help facilitate this multi-faceted conversa-
tion through patient-centered, empathic interactions –
arguably in a manner consistent with a shared-decision
making model [2].
As a fundamental component of quality health care,
patient-centered communication is an important area
for investigation in cancer care. Previous studies have
shown that patient-centered communication can improve
the patient experience, patient health status and out-
comes, and the efficiency of medical care [3-6]. Further-
more, other studies indicate that poor communication inLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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emotional, and collateral costs to patients, their support
networks, clinicians, the cancer care system, and society
more widely [6].
Due to the gravity of the diagnosis, communication
between cancer patients and their treating clinicians
may be emotionally intense; patient needs likely vary de-
pending on tumor type, age, sex, health literacy, social
and cultural norms and where a patient is located along
the cancer care continuum. The 2006 Institute of Medi-
cine report, From Cancer Patient to Cancer Survivor:
Lost in Transition, concluded that many of the routine
needs of cancer patients after initial cancer treatment
were not being adequately addressed [7]. The topics that
are often of most importance to patients include quality
of life, sexual dysfunction, the safety of complementary
and alternative medicines (CAM) and other important
questions which may or may not be routinely addressed
in consultation. Discussing uncertainty, risk and care op-
tions also pose challenges to patient-clinician communi-
cation [8]. This disconnect in communication has been
documented among Latinos living with HIV and their
clinicians [9,10], however, there is a significant research
gap in underlying factors that influence cancer patient-
clinician communication, especially in ethnic minority
cancer patients. Further, the role of friends and family in
cancer conversations remains an important but under-
studied element of cancer patient care [11]. Improved
understanding of the patient-clinician-companion dy-
namic could help identify existing strengths and areas
for improvement in this domain and lead to improved
patient adherence to therapy and clinical care visits [12].
Without a detailed assessment of the challenges and op-
portunities for achieving a more patient-centered dynamic
in existing clinical consultations, improving clinician-
patient interactions in cancer care could be difficult,
haphazard, and unsustainable. A detailed description of
cancer decision-making processes surrounding key topics
important to patients, but that fall outside the scope of
cancer therapeutics could enable feasible, sustainable
practice-based interventions to be identified, tested, and
implemented. Developing a comprehensive picture of
what patient-clinician-companion dynamics in cancer care
look like is the first step in improving the quality of these
interactions.
The existing literature assessing the measurement of
patient-centered communication in cancer care suggests
that the communication process can be divided into six key
domains: exchanging information, fostering healing relation-
ships, managing uncertainty, recognizing and responding to
emotions, making decisions, enabling self-management and
patient navigation, as well as cross-cutting themes among
these [11]. We build on insights from this growing body of
work in an ongoing observational study designed to fill ingaps in the existing data on patient-clinician-companion
communication in cancer care by focusing on features of
real-time clinical discussions as they occur in practice.
Below we describe a study in which we involve multiple in-
stitutions, utilize mixed empirical methods, and employ a
short-term longitudinal, prospective follow-up component
to begin assessing what really goes on in oncology care dis-
cussions across a diversity of patient populations and a var-
iety of tumor types and practice settings. Our approach is
interdisciplinary, drawing upon existing conceptual frame-
works of communication in cancer and addressing ques-
tions with qualitatively and quantitatively tools. This paper
describes the current state of patient-clinician cancer
communication and identifies specific gaps that ongoing
research must address. Through our comprehensive,
real-time approach, we hope to provide a foundation
upon which to develop methods for enhancing patient-
centered communication in cancer care.
Hypothesis and rationale
We hypothesize that clinician-patient conversations about
key topics such as quality of life, cost, sexual function, or
complementary and alternative therapies will lack import-
ant elements of informed decision-making compared to
conversations focused on cancer treatment options and
symptom management. We further hypothesize that the
degree of patient-centeredness in cancer consultations
(using standardized metrics) will be an important pre-
dictor of discussion content and how these topics are
discussed. Our rationale for this research is that eventual
interventions to promote patient-centered communication
in cancer must start with a detailed characterization of ac-
tual discussions between cancer patients and their clini-
cians within a broad cross-section of oncology care. To
date such studies have only addressed therapeutic treat-
ment decision making in breast cancer [13] and end of life
decision making [14].
Objectives
The overall objective of this line of research is to im-
prove the patient experience in the communication
process by first characterizing existing care conversa-
tions in a variety of clinical settings in medical oncology.
The specific aims of the research are outlined in Table 1.
Methods/design
This study has been approved by the Mayo Clinic Insti-
tutional Review Board. The overall design of this study is
prospective and observational. We will use real-time ob-
servation of clinical interactions as the main means of
data collection augmented by self-reported survey mea-
sures and medical record review (Figure 1). This pro-
spective design will allow us to capture a clear picture of
Table 1 Study aims
Aim
1.
To richly characterize the dynamics and quality of patient-clinician-companion interactions in routine cancer care consultations by
documenting the frequency, duration, and content of conversations about key issues that are important to patients in their care.
1a. To describe the frequency, duration and content of routine cancer consultations surrounding key challenging topics in the clinical dialogue.
1b. To examine in-depth the fundamental psycho-social dynamics of deliberations that occur between patients and clinicians during routine
cancer care consultations.
1c. To assess the comprehensiveness of these discussions pertaining to key elements of informed decision-making.
1d. To assess the degree of content concordance between topics raised in the recorded conversations and what is documented in the medical
record for each of the key topics.
Aim
2.
To identify key characteristics of cancer consultation participants and dialogue that influence subsequent clinical actions and short
term outcomes.
2a. To identify clinician characteristics associated with the discussion of topics in the key topic list raised during a routine cancer consultation.
2b. To identify patient clinical, demographic, and psychosocial characteristics associated with the discussion of topics in the key topic list raised
during a routine cancer consultation.
2c. To determine if the patient-centeredness of patient-clinician dialogue predicts which topic areas are discussed and the subsequent decisions
that are made in a patient’s care across English and Spanish-speaking (and mixed) care contexts.
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with minimal intrusion.
Our data collection approach seeks to discover induct-
ively the characteristics of high quality communication
while examining discussions for known features of high
quality communication. We will extend this mentality
into the analysis phase described below by using a com-
bination of emergent and a priori coding techniques in
which we allow new themes to emerge while identifying
specific issues and dynamics related to our foundational
assumptions and specific aims. Qualitative methods will
allow us to examine the features of conversations in this
context without restricting that analysis to a single ana-
lytic viewpoint. Without being constrained by a particu-
lar conceptual model, we will employ a variety of well
tested, broadly accepted analytic techniques in order to
characterize real-time interactions between oncologyFigure 1 Schematic of data collection modes & timeline.clinicians and their patients. In applying an approach
that is both qualitative and quantitative, we hope to
build a comprehensive picture of clinical interactions in
oncology with sufficient depth to inform future efforts
to improve the quality of these deliberations.
Participants & recruitment
Clinicians
In order to obtain patient/clinician dyads engaged in clin-
ical conversation, we will begin by recruiting clinicians.
We will enroll medical oncology clinicians, including phy-
sicians, nurse practitioners, physician assistants, and se-
nior fellows in medical oncology who actively practice
with at least 20% clinical time. Clinicians will be recruited
from three hospitals: Mayo Clinic-Rochester, University of
Southern California-Norris Comprehensive Cancer Cen-
ter, and Los Angeles County Hospital.
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clinician. Eligible patients must be age 18 years or older,
speak English or Spanish, must not be enrolled in
hospice, and have received histological confirmation of
any solid tumor malignancy including brain, breast,
endocrine, gastrointestinal, genitourinary, gynecological,
head/neck, lung, melanoma, or sarcoma malignancy at
all points of the cancer continuum which we define as
initial diagnosis, early initial treatment, mid-initial treat-
ment, post-treatment/survivorship/remission, recurrence
& undergoing treatment, and end-stage disease. We
intentionally developed broad inclusion criteria within the
more restricted chronic disease category of cancer so as to
keep the study focused on an important population. In
total, we expect to include 60 medical oncology clinicians
(45 faculty-level medical oncologists, approximately 10–15
oncology nurse practitioners, and 6–8 senior hematology/
oncology fellows) and 600 medical oncology patients
across the three sites.
After compiling lists of eligible clinicians at each study
site, we will invite these individuals to participate via
phone, email, or in-person interactions. Written informed
consent will be obtained from clinicians who volunteer to
participate. We decided on written informed consent as
our standard operation for several reasons. From a human
subjects protection perspective, if our IRB protocol at one
study site permitted only verbal consent but the other two
study sites require written consent, we did not want to
jeopardize having to revise the overall study protocol to ac-
commodate potential concerns that could be raised on the
secondary study sites. Thus, although this would be a legit-
imate circumstance in which to utilize verbal consent, we
opted for the more conservative written consent. More-
over, given the potential sensitivity of topics discussed, and
the general familiarity that oncology clinicians have with
written consent, we thought they would consider written
consent a more standard and robust approach.
Patients
Prior to approaching patients for consent during an
agreed upon half-day with clinicians, study personnel
will review with clinicians a list of the day’s eligible pa-
tients to give clinicians an opportunity to decline study-
ing interactions with a particular patient for whom the
interaction would be too sensitive. Approved patients
will then be approached in their exam room or in an-
other private room in the order that they will be seen by
their clinician. If the patient expresses interest in partici-
pating after a brief introduction to the study, study
personnel will undertake a full written consent process
(and oral consent for any companions who are present).
In this process the study coordinator will walk through
the risks and benefits of the proposed study, allowing
ample time for discussion and clarification. To ensurevoluntariness, they will re-iterate that the patient’s care
will change in no way. Consented patients will be offered
a 4-hour parking voucher as a small token of thanks.Data collection
Our main modes of data collection in this study will in-
clude patient and clinician surveys, an audio-recorded
clinical conversation, medical record review, and op-
tional interviews with clinicians. Survey instruments for
this study were developed and adapted from a variety of
validated measures of patient reported outcomes, quality
of life, satisfaction, and health behaviors from existing
widely used tools whenever possible [15-18]. Specific
time points of quantitative data collection can be found
in Table 2.Initial clinician and patient surveys
Once a clinician consents to participate in the study,
study staff will administer a baseline survey that will col-
lect basic demographic and professional practice charac-
teristics of clinicians including age, sex, race/ethnicity,
number of years in practice, and any general training in
communication. Study personnel will also administer a
survey (hereafter referred to as the “pre-encounter pa-
tient survey”) to each patient immediately following the
informed consent process and immediately prior to their
oncology appointment. The pre-encounter patient sur-
vey will assess patient demographics, health literacy
[19,20], and quality of life [21].Audio recorded clinical conversation
For the second part of data collection, study staff will
place a handheld digital audio recorder in the enrolled
patient’s exam room and turn it on at the start of the
patient-clinician encounter. Patients and clinicians will
have the option of turning the recorder off at any time
and will be trained on how to do this. A red light on the
recorder, which signals that it is recording, will ensure
that the clinician and patient know at all times whether
the recorder is on or off. At the end of the visit, the re-
corder will be turned off and the recordings immediately
transferred and saved to an internal server accessible
only to our research team.
We will use an online editing tool (Audacity™) to re-
move any personal identifiers from the recordings before
they are transcribed and sent to our collaborating ana-
lysis site. The files will be uploaded to a password-
protected flash drive and mailed to our analysis site for
analysis. During this process we will “flag” regions on
the recording where the key topics are discussed. These
“flags” will anchor subsequent topical qualitative and
quantitative analyses.
















Emotional well-being ✓ ✓
Physical well-being ✓ ✓
Intellectual well-being ✓ ✓
Social activity ✓ ✓
Spiritual well-being ✓ ✓
Pain ✓ ✓
Fatigue ✓ ✓
Support from friends/family ✓ ✓










Agenda setting in visit ✓
Patient-centeredness ✓













Quality of visit ✓
3-Month Follow up Patient
Survey
Quality of life ✓ ✓
Overall ✓ ✓
Emotional well-being ✓ ✓
Physical well-being ✓ ✓
Intellectual well-being ✓ ✓
Social activity ✓ ✓
Table 2 Table of quantitative variables and time points of
collection (Continued)













Location of patient care ✓
Insurance ✓
Family cancer history ✓










Discussing End-of-life care ✓
Kimball et al. BMC Cancer 2013, 13:455 Page 5 of 10
http://www.biomedcentral.com/1471-2407/13/455Post-encounter patient and clinician surveys
Immediately following the clinical consultation, patients
will be asked to fill out a second survey. This “post-en-
counter patient survey” will collect information about
the patient’s perspective on the just-concluded visit. The
post-encounter patient survey was developed using
preexisting measures including the CAHPS Clinician &
Group Surveys - Visit Survey 2.0 (https://cahps.ahrq.
gov/clinician_group/) (modified to instruct patients to
answer about the encounter that just occurred with their
cancer clinician), and the SDM Q-9 [18]. In this survey,
patients assess patient and clinician roles in the conver-
sation, the extent to which communication with their
clinician was patient-centered, if a specific decision was
made, as well as report about the degree of shared
decision-making present in that deliberation using the
above metrics. It will also document if a patient feels
that any of his or her important concerns were not
discussed in the visit as well as whether any key topics,
including CAM, symptom management, and emotional
or social concerns were discussed. More global questions
about the visit include a clinician rating and an overall
score of the patient’s satisfaction with the visit. A final
question serves as a quality control measure, asking how
comfortable the patient felt being recorded to determine
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have influenced the dynamic.
Clinicians will also be asked to complete a second
survey immediately following their appointment with a
study patient. The one-page “post-encounter clinician
survey” will address patient and visit-specific topics from
a clinician perspective including the patient’s location on
the cancer care continuum (i.e. initial diagnosis, early ini-
tial treatment, mid-initial treatment, post-treatment/sur-
vivorship/remission, recurrence & undergoing treatment,
and end-stage disease) and the clinician’s perception of
the quality and effectiveness of the encounter (i.e. “I felt
that my time with this patient today was well spent”; “I
established rapport with this patient today”; “I was able to
obtain an accurate and detailed medical history from this
patient”; “I think this patient requires a lot of emotional
support”; “I think that this patient is coping well with his/
her cancer treatment and side effects”; “Overall I was
satisfied with this encounter today”). In addition, this
survey will ask clinicians if they felt a specific decision
about the patient’s care was made during the visit, enab-
ling us to subsequently assess the degree of concordance
with patient-self ratings of the same measure and con-
cordance with chart review. Although there is signifi-
cant debate about whether discrete “decisions” reflect
the complex lived experiences of patients [22], being
able to document concordance and discordance in these
ratings as well as complementing these quantitative var-
iables with more inductive, qualitative methods should
further elucidate those debates.
Follow-up patient survey and chart review
Three months following direct-observation recording,
we will mail each study patient a paper follow-up survey
including a cover letter and an addressed, stamped re-
turn envelope. This survey will allow us to longitudinally
assess any changes in quality of life. Additionally, it will
help us assess our list of key topics as well as patient
decision-making preferences. Having these measures at
the end of the study period limits the effects of observer
bias on patient and provider behavior.
At the same time follow-up surveys are being mailed,
study staff will conduct medical record reviews for each
study patient. Assessment of each patient’s chart will
permit us to examine major medical events as well as
any documentation of key topics in clinical notes.
Follow-up clinician survey and optional interview
After each enrolled clinician has reached his or her
maximum number of study patient interactions (i.e. 8–
12), a follow-up clinician survey will be administered.
Because clinicians may differ with respect to their com-
fort level discussing potentially sensitive topics with their
patients, the follow-up survey will assess the attitudesand behaviors of clinicians with regard to discussing
these topics with their patients at a point in the study
where our questions do not influence their clinical be-
havior observed. Specifically, this survey will ask about
discussing complementary and alternative medicine use,
psychosocial issues, and end-of-life care.
Enrolled clinicians will also be asked if they are inter-
ested in participating in an optional semi-structured
interview at the conclusion of the study. The interviews
will provide an opportunity to debrief clinicians on the
aims of the study as well as a chance to delve into their
views on shared decision-making, communication sur-
rounding key topics, and challenges and opportunities
for communication in a medical oncology setting. Using
this approach will allow us to discuss previously unknown
concerns that can only emerge through inductive ap-
proaches. For instance clinicians talking about CAM as
part of a larger process of helping patient reconcile their
healing experience with the recommendations of an indi-
genous healer from their home village or discussing the
role of relatively benign “immune boosting” supplements
in order to encourage the patient to complete chemo
therapy.
*Please note: complete data collection instruments are
accessible in Additional file 1. More detailed standard
operating procedures are available upon request.
Study Pre-test
In an effort to elucidate and address potential methodo-
logical or logistic challenges prior to actual study imple-
mentation, we conducted a study pre-test approximately
three months before the start of participant enrollment
and data collection. All clinician and patient recruitment,
enrollment, and data collection procedures (including
audio-recording of appointments and dissemination of
surveys) were pre-tested with three oncology clinicians
and 15 patients at Mayo Clinic. This pre-test process
proved invaluable in helping us identify and address pro-
cedural issues such as the location and timing of patient
enrollment, questions or confusion about survey items
needing re-wording, as well as simply to establish rapport
and a good working relationship with the clinical desk
staff in medical oncology.
Analysis
All clinician and patient survey responses will be col-
lected, double-entered, and managed by study staff using
REDCap electronic data capture tools hosted at Mayo
Clinic [23]. REDCap (Research Electronic Data Capture)
is a secure, web-based application designed to support
data capture for research studies, providing: 1) an intui-
tive interface for validated data entry; 2) audit trails for
tracking data manipulation and export procedures; 3) au-
tomated export procedures for seamless data downloads
Kimball et al. BMC Cancer 2013, 13:455 Page 7 of 10
http://www.biomedcentral.com/1471-2407/13/455to common statistical packages; and 4) procedures for
importing data from external sources.
After data collection and entry we will explore what
the data mean for each study aim (see Table 1):
Aim 1
To characterize the content of the recorded conversa-
tions, we will employ the Roter Interaction Analysis Sys-
tem (RIAS), one of the most widely used and extensively
validated approaches to quantitative discourse analysis
of medical encounters [24,25]. Coders blinded to the
study’s hypotheses will use RIAS to categorize each ut-
terance of the clinical encounter into 40 categories.
With this system’s flexibility, codes can be individually
applied to a piece of the interaction or combined with
one another to summarize dialogue. These categories
will organize the data, providing a foundation upon
which we can begin to assess the dynamics of these con-
versations. Through this method we will examine the
data quantitatively, assessing dialogue through the four-
function Communication Model which informs RIAS
[26]. This validated method has been applied in a variety
of medical settings, including oncology [26,27].
In addition to quantitative techniques for analyzing
the recorded conversations, we will use qualitative con-
tent analysis to characterize the fundamental nature of
discussions about key topics. In our data analysis we will
use a combination of a priori and emergent coding tech-
niques that will allow us to search for key topics of inter-
est, while exploring the questions, “What is this about?”
and “What is being referenced here?” in a manner that
will allow new themes to emerge [28,29]. A priori tech-
niques look for pre-defined categories like “expressions
of empathy” or other known important psychosocial cat-
egories. Emergent techniques will maintain a posture of
receptivity to elements of meaning that may not have
been pre-specified. For instance, even if our theoretical
models do not specify it, we might in the context of ana-
lysis, discover that “tone of voice” or “sharing of personal
anecdotes” shape how dialogue is shaped. Used widely in
ethnographic and direct observational data analysis, this
approach to conversation analysis contextualizes partici-
pants’ understanding, makes comparisons, and tracks vari-
ations in meaning across specific cases [30-33].
After coding with RIAS, during which we will identify
instances of key topics brought up during the discussion,
we will carefully dissect the content of those discussions
using a combination of two existing measures of deci-
sion quality: the OPTION scale and the IDM-18. The
IDM-18 is a validated measure of key elements of in-
formed decision-making, while the OPTION scale rates
the degree to which patients were engaged in decision-
making about their care [34,35]. Study team members
will apply these measures to flagged recordings and eachwill rate interactions with an approach similar to video
analyses we have done in the past [36]. We will ensure a
high degree of inter-rater reliability on a subset of re-
cordings before applying the full scoring systems to the
entire data set. Both of these analysis techniques are sub-
ject to their own strengths and weaknesses [37]. However,
when used in tandem, we believe that they will begin to
sketch a more comprehensive picture of decision-making
quality in this context.
A follow-up medical record review three months after
the audio-recorded clinical encounter will allow us to re-
view patient participants’ medical records for study-
related information. This review will have the capacity to
assess documentation of any actions related to the key
topics starting initially with complementary and alterna-
tive therapies. Using these records, we will apply ac-
cepted methods of medical record chart review [38] and
document all major events in the patient participants’
treatment course to date as well as determine whether
aspects related to the key topics mentioned above were
documented. Medical record review data will be double-
entered using a REDCap database.Aim 2
To determine how different characteristics of cancer
consultation participants and their dialogue influence
the discussions and subsequent clinical actions, we will
conduct univariate and multivariate statistical analyses.
Information for these analyses will be obtained from the
codes assigned to the audio recordings and information
from the surveys and chart abstraction. We will employ
Pearson chi-square and/or Fisher’s exact tests (for uni-
variate testing) followed by multivariate logistic regres-
sion models to identify clinician and patient clinical,
demographic, as well as psychosocial characteristics as-
sociated with having discussed key topics.Potential limitations
In a large mixed-method, multi-site study like ours, we
may face a variety of problems that could impede our pro-
gress. We may face difficulties in the rate of accrual, par-
ticipant (patient and/or clinician) discomfort with being
recorded, the Hawthorne effect, concerns related to multi-
lingual data collection and analysis, social-desirability or
premature disclosure of study hypotheses. Each potential
challenge will be addressed as follows.
As currently conceived, we envision recruiting 20–40 pa-
tient participants per month for approximately 30 months.
If we encounter challenges with the rate of accrual, we
have the capacity to extend our data collection an extra
year into the study’s final year while simultaneously under-
taking all necessary analyses. Participant anxiety about be-
ing recorded can be addressed by reiterating that patients
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time during the appointment.
Regarding the Hawthorne effect, although there are
methods for ensuring that observed behavior is truly
naturalistic, our experiences recording decision-aid trials
at Mayo Clinic as well as other studies using direct ob-
servation have shown that patients and clinicians adapt
to being recorded very quickly, soon ignoring the pres-
ence of recording devices. While it is true that recorded
visits may capture "best behavior," it is unlikely that this
is systematically interpreted by physicians in a way that
would jeopardize the validity of findings. The issue of
performance bias in response to tape recording has been
addressed in several studies [39-42]. All have found that
the effect is minimal. Included among these is a study in
which the content of video recordings of physicians who
were and were not informed that recordings were being
made found no statistically significant differences in length
of visit or in the number or nature of the problems
discussed [41].
Our analysis may be complicated by multi-lingual data
collection and analysis. The complications related to
translation, back translation, and validity of study instru-
ments used in multiple languages are well known [43-45].
We will mitigate these problems by using optimal data
handling practices for translation and back translation,
using previously validated Spanish-language versions of all
study tools whenever possible, and utilizing the expertise
of a team member conversant with Latino cultures in
Southern California as well as using Spanish-speaking
analytic expertise for our RIAS coding.
In order to prevent participation bias, we intend not
to disclose the aims of our study to research participants
throughout the duration of data collection. This could
be very important among clinicians. We will assess this
qualitatively in the interviews and quantitatively in the
follow up survey. Although we cannot anticipate all of
the challenges we might face, the vast experience of the
study team in accruing participants for research studies
and in recording real-time decision-making processes in
clinical consultations has prepared us to resolve issues
as they arise.
It is also possible that our detailed and in-depth con-
sent procedures may in some way bias or prime patients
for a different kind of conversation than they might have
otherwise had. In order to satisfy regulatory stakeholders
and conduct the study with integrity, we must accept
the limits this possibility this may bring.
Discussion
We have described an ongoing large multi-center obser-
vational study designed to investigate and characterize
clinical interactions between clinicians and patients as
they occur in oncology as well as identify key factorsthat influence decision-making about important topics
in cancer care. Presenting these methods here will allow
for other authors to build upon and critique our approach
while data are still being generated. In attempting to cap-
ture a picture of any aspect of health care, inherent diffi-
culties may arise in balancing the breadth and depth of
the of inclusion criteria for a heterogeneous clinical popu-
lation. One of the challenges in implementing a study like
this involves determining the most useful sample group.
We intentionally developed broad inclusion criteria within
the more restricted chronic disease category of cancer so
as to keep the study focused on an important population.
Having large, but manageable, groups of clinicians is
the single most important feature in determining whether
a study can capture a breadth of variability in communica-
tion behavior, as it is typically clinicians, not necessarily
patients, who contribute the greatest variability in com-
munication behavior [46]. However, our existing study
sites, although diverse, are not nationally representative.
Mayo Clinic’s large oncology practice makes it an ideal site
for completing a study of this magnitude. Although in-
cluding more sites may have been preferable, we were
concerned that a large number of sites would severely de-
crease the study’s feasibility. We anticipate that the patient
sample accrued at USC Norris and LA County Hospital
will be more heterogeneous than at Mayo Clinic and, spe-
cifically at LA County, will include a large proportion of
un- or under-insured minority patients.
This study provides an important opportunity to assess
both the difficulties and opportunities for improving the
quality of discussions in a cancer care setting and will
thereby yield an invaluable baseline description for fu-
ture interventional studies. Our study will explore the
nature of these interactions in order to pinpoint the
strengths and weaknesses of these deliberations as they
exist today. In doing this, we hope to inform future in-
terventions for improving the quality of discussions in
the cancer care context.
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